Kimihiko Fujisawa
Oprichter bij Aqumen Biopharmaceuticals KK
Momenteel actieve connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Hiroyuki Matsuda | M | - |
Aqumen Biopharmaceuticals KK
 Aqumen Biopharmaceuticals KK Pharmaceuticals: MajorHealth Technology Aqumen Biopharmaceuticals KK is a holding company that provides research and development of therapeutic medicines for macular degeneration. It also develops therapeutics for diabetic retinopathy, diabetic nephropathy, adjuvants for ophthalmic surgery, and intraocular drug delivery systems. The firm's products encompass the ILM-Blue and the MembraneBlue-Dual. The company was founded by Kimihiko Fujisawa and Tadahisa Kagimoto on April 11, 2005 and is headquartered in Fukuoka, Japan. | 18 jaar |
| Yoshiro Hori | M | 60 |
Aqumen Biopharmaceuticals KK
Aqumen Biopharmaceuticals KK Pharmaceuticals: MajorHealth Technology Aqumen Biopharmaceuticals KK is a holding company that provides research and development of therapeutic medicines for macular degeneration. It also develops therapeutics for diabetic retinopathy, diabetic nephropathy, adjuvants for ophthalmic surgery, and intraocular drug delivery systems. The firm's products encompass the ILM-Blue and the MembraneBlue-Dual. The company was founded by Kimihiko Fujisawa and Tadahisa Kagimoto on April 11, 2005 and is headquartered in Fukuoka, Japan. | - |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Hardy Kagimoto | M | 47 |
Aqumen Biopharmaceuticals KK
Aqumen Biopharmaceuticals KK Pharmaceuticals: MajorHealth Technology Aqumen Biopharmaceuticals KK is a holding company that provides research and development of therapeutic medicines for macular degeneration. It also develops therapeutics for diabetic retinopathy, diabetic nephropathy, adjuvants for ophthalmic surgery, and intraocular drug delivery systems. The firm's products encompass the ILM-Blue and the MembraneBlue-Dual. The company was founded by Kimihiko Fujisawa and Tadahisa Kagimoto on April 11, 2005 and is headquartered in Fukuoka, Japan. | - |
| Hitoshi Torii | M | - |
Aqumen Biopharmaceuticals KK
Aqumen Biopharmaceuticals KK Pharmaceuticals: MajorHealth Technology Aqumen Biopharmaceuticals KK is a holding company that provides research and development of therapeutic medicines for macular degeneration. It also develops therapeutics for diabetic retinopathy, diabetic nephropathy, adjuvants for ophthalmic surgery, and intraocular drug delivery systems. The firm's products encompass the ILM-Blue and the MembraneBlue-Dual. The company was founded by Kimihiko Fujisawa and Tadahisa Kagimoto on April 11, 2005 and is headquartered in Fukuoka, Japan. | - |
Statistieken
| Land | Connecties | % van het totaal |
|---|---|---|
| Japan | 4 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Kimihiko Fujisawa
- Persoonlijk netwerk
